Put companies on watchlist
ABIVAX
ISIN: FR0012333284
WKN: A14UQC
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

ABIVAX · ISIN: FR0012333284 · EQS - Company News (132 News)
Country: France · Primary market: France · EQS NID: 1737263
29 September 2023 06:00PM

Abivax announces the release of its 2023 half-year financial report


EQS-News: ABIVAX / Key word(s): Half Year Report
Abivax announces the release of its 2023 half-year financial report

29.09.2023 / 18:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Abivax announces the release of its 2023 half-year financial report

 PARIS, France, September 29, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announces today the release of its 2023 half-year financial report.

The 2023 half-year financial report is available on the website of the Company (www.abivax.com – “Investors”).


About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S., Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on X, formerly Twitter, @ABIVAX_.


Contacts

Investor Relations
Abivax
Patrick Malloy
patrick.malloy@abivax.com
+1 847 987 4878
Investors Relations US
LifeSci Advisors
Ligia Vela-Reid
lvela-reid@lifesciadvisors.com
+44 7413 825310
Investors Relations France
Seitosei Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24
 
Investor Relations Europe
MC Services AG
Dr. Solveigh Mähler
solveigh.maehler@mc-services.eu
+49 211 529 252 19
   


29.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


1737263  29.09.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1737263&application_name=news&site_id=boersengefluester
Visual performance / price development - ABIVAX
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.